CRESPIATICO, ILARIA
CRESPIATICO, ILARIA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Long-term Results after Hyaluronan-based MACT for the Treatment of Cartilage Lesions of the Patellofemoral Joint
2016 Kon, E; Filardo, G; Gobbi, A; Berruto, M; Andriolo, L; Ferrua, P; Crespiatico, I; Marcacci, M
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
2019 Magistroni, V; Mauri, M; D'Aliberti, D; Mezzatesta, C; Crespiatico, I; Nava, M; Fontana, D; Sharma, N; Parker, W; Schreiber, A; Yeung, D; Pirola, A; Redaelli, S; Massimino, L; Wang, P; Khandelwal, P; Citterio, S; Viltadi, M; Bombelli, S; Rigolio, R; Perego, R; Boultwood, J; Morotti, A; Saglio, G; Dong-Wook, K; Branford, S; Gambacorti Passerini, C; Piazza, R
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine
2020 Fontana, D; Mauri, M; Renso, R; Docci, M; Crespiatico, I; Rost, L; Jang, M; Niro, A; D'Aliberti, D; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Fanelli, F; Cassina, V; Corti, R; Salerno, D; Nardo, L; Chinello, C; Mantegazza, F; Mecucci, C; Magni, F; Cavaletti, G; Bruheim, P; Rea, D; Larsen, S; Gambacorti-Passerini, C; Piazza, R
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine
2020 Fontana, D; Mauri, M; Renso, R; Docci, M; Crespiatico, I; Rost, L; Jang, M; Niro, A; D'Aliberti, D; Massimino, L; Bertagna, M; Zambrotta, G; Bossi, M; Citterio, S; Crescenzi, B; Fanelli, F; Cassina, V; Corti, R; Salerno, D; Nardo, L; Chinello, C; Mantegazza, F; Mecucci, C; Magni, F; Cavaletti, G; Bruheim, P; Rea, D; Larsen, S; Piazza, R; Gambacorti-Passerini, C
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
2020 Crespiatico, I; Bossi, E; Brioschi, F; Piazza, R; Mologni, L; Gambacorti‐passerini, C
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma
2021 Arosio, G; Sharma, G; Villa, M; Mauri, M; Crespiatico, I; Fontana, D; Manfroni, C; Mastini, C; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Massimino, L; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples
2023 Aroldi, A; Angaroni, F; D’Aliberti, D; Spinelli, S; Crespiatico, I; Crippa, V; Piazza, R; Graudenzi, A; Ramazzotti, D